研究揭示司美格魯肽藥物對健康的新益處
Research reveals new health benefits of semaglutide drugs
Updated at: September 11, 2026 at 03:45 AM
近期的研究從根本上改變了我們對司美格魯肽（Semaglutide）的看法，這是 Ozempic 和 Wegovy 等藥物中的活性成分。
Recent research has fundamentally changed how we view semaglutide, the active ingredient in medications like Ozempic and Wegovy.
雖然其初期是因用於管理二型糖尿病和肥胖症而聞名，但目前的研究更強調它作為一種強大的「心-腎-代謝」治療藥物的角色。
While initially known for managing type 2 diabetes and obesity, studies now highlight its role as a powerful 'cardio-kidney-metabolic' therapy.
如 SELECT 研究等大型臨床試驗顯示，司美格魯肽可將心臟病發作和中風的風險降低 20%，且與體重減輕無關。
Large-scale trials, such as the SELECT study, demonstrate that semaglutide reduces the risk of heart attacks and strokes by 20%, independent of weight loss.
此外，該藥物還為腎臟提供了至關重要的保護，顯著延緩了慢性腎臟病的惡化。
Furthermore, the drug provides vital protection for the kidneys, significantly slowing the progression of chronic kidney disease.
除了對心臟和腎臟的影響外，司美格魯肽在治療脂肪肝病方面也展現出潛力，能夠減輕發炎和疤痕組織的形成。
Beyond the heart and kidneys, semaglutide shows promise in treating fatty liver disease by reducing inflammation and scarring.
最令人興奮的或許是近期開始探討其對心理健康和神經保護影響的研究，早期證據表明它對雙極性障礙甚至神經退化疾病等病症具有潛在益處。
Perhaps most exciting are emerging studies exploring its impact on mental health and neuroprotection, with early evidence suggesting potential benefits for conditions like bipolar disorder and even neurodegenerative diseases.
透過同時處理相互關聯的健康問題，司美格魯肽正從單純的減肥工具演變成一種全面的系統性健康治療方案。
By addressing interconnected health issues simultaneously, semaglutide is evolving from a simple weight-loss tool into a comprehensive treatment for systemic health.
這種醫療轉變讓臨床醫師能夠透過針對發炎和代謝功能障礙的根源，更有效地治療病患，標誌著現代醫學的一個新時代。
This medical shift allows clinicians to treat patients more effectively by targeting the root causes of inflammation and metabolic dysfunction, marking a new era in modern medicine.
